[Nobutaka Hattori] Development of metabolite biomarkers of Parkinson’s disease and identification of drug seeds from chemical screening based on the biomarkers


Research Director

Nobutaka Hattori

Nobutaka Hattori

School of Medicine, Juntendo University
Professor
website


Outline

Increase of number of patients with Parkinson’s disease (PD) causes increment of medical and nursing costs because of the rapid population ageing in Japan. In this study, we try to develop serum metabolite biomarker(s) of PD patients to make accurate differential diagnosis as well as disease-grading possible with metabolomics techniques. Also, to figure out the relationship of the identified biomarker(s) with disease pathogenesis, we perform confirmation studies with DNA/RNA, disease models of mice and neurons differentiated from induced pluripotent stem cells. Likewise, chemical screening is performed to identify drug seeds to correct the biomarkers, leading to modification of the disease course.

Quick Access

Quick Access

 News

arrow On-going

arrow Completed

Program

  • CREST
  • PRESTO
  • ACT-I
  • ERATO
  • ACT-C
  • ACCEL
  • ALCA
  • RISTEX
Finish programs
  • Pamphlet
  • ProjectDB
  • GlobalActivity
  • Diversity-EN
  • OS_Policy-EN
  • Question-E